Patents by Inventor Wolf-Dietrich Doecke

Wolf-Dietrich Doecke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulphimides as protein kinase inhibitors
    Patent number: 7943629
    Abstract: The invention relates to sulphimides as protein kinase inhibitors of the general formula I
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: May 17, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Ulrich Luecking, Duy Nguyen, Arne von Bonin, Oliver von Ahsen, Gerhard Siemeister, Rolf Jautelat, Wolf-Dietrich Doecke
  • SULPHIMIDES AS PROTEIN KINASE INHIBITORS
    Publication number: 20080058358
    Abstract: The invention relates to sulphimides as protein kinase inhibitors of the general formula I
    Type: Application
    Filed: June 7, 2007
    Publication date: March 6, 2008
    Inventors: Ulrich Luecking, Duy Nguyen, Arne von Bonin, Oliver von Ahsen, Gerhard Siemeister, Rolf Jautelat, Wolf-Dietrich Doecke
  • Microglia inhibitors for interrupting interleukin 12 and IFNgamma-mediated immune reactions
    Publication number: 20060211690
    Abstract: The invention describes the use of microglia inhibitors for the production of pharmaceutical agents that inhibit immune reactions that are mediated by monocytes, macrophages and T cells, and their use for treating T-cell-mediated immunological diseases and non-T-cell-mediated inflammation reactions.
    Type: Application
    Filed: February 9, 2006
    Publication date: September 21, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Thorsten Blume, Wolf-Dietrich Doecke, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Moenning, Bernd Elger, Herbert Schneider
  • Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
    Publication number: 20040006117
    Abstract: The invention describes the use of microglia inhibitors for the production of pharmaceutical agents that inhibit immune reactions that are mediated by monocytes, macrophages and T cells, and their use for treating T-cell-mediated immunological diseases and non-T-cell-mediated inflammation reactions.
    Type: Application
    Filed: February 14, 2003
    Publication date: January 8, 2004
    Applicant: SCHERING AKTIENGESELLSCHAFT
    Inventors: Thorsten Blume, Wolf-Dietrich Doecke, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Moenning, Bernd Elger, Herbert Schneider